One would consider EGFR-targeted therapy since that the majority of prostate cancers are derived from an epithelial origin and are associated with elevated activities of the EGFR family [6–9]; however, using either an EGFR antagonist or anti-HER2 antibody did not achieve therapeutic effectiveness in CRPC [10, 36]. Here, ERBB2 is linked to prostate carcinoma.